Leerink Partners has downgraded Aurinia Pharmaceuticals Inc (AUPH) from Outperform to Market Perform as of December 2, 2025. This adjustment reflects a more cautious outlook for the company amid potential competitive pressures and execution risks that may affect its performance.
Aurinia Pharmaceuticals, headquartered in Edmonton, Alberta, is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. The firm’s lead product, LUPKYNIS (voclosporin), is an oral treatment for adult patients with active lupus nephritis, and it continues to pursue clinical and regulatory activities to enhance its development program. The company also develops aritinercept (AUR200), aimed at treating autoimmune diseases.
As of the downgrade, Aurinia's stock is priced at $15.13, with a market capitalisation of $2.1 billion. The company reported a price-to-earnings ratio (P/E) of 26.97 and an earnings per share (EPS) of 0.56. Upcoming earnings are anticipated on July 29, 2026, with an EPS estimate of $0.21 and revenue projection of $77.6 million.
Analyst ratings, while informative, are based on specific assumptions and should be considered alongside other factors such as company fundamentals and industry trends. The current analyst consensus remains a Buy, with 4 Strong Buy, 6 Buy, and 3 Hold ratings among 13 total analysts.
Recent analyst actions include a downgrade from RBC Capital to Sector Perform on November 5, 2025, and an upgrade from Jefferies to Buy on November 7, 2025. Such decisions reflect the dynamic nature of market assessments as new information emerges.